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Abstract 
Purpose: Infections caused by AmpC-positive bacteria results in high patient morbidity and mortality 
making their detection clinically important as they cannot be detected in routine susceptibility testing. 
This study aim to determine the prevalence of AmpC β-lactamase among Gram negative bacteria 
recovered from clinical specimens in Benin City, Nigeria. 
Methods: A total of 256 consecutive and non-repetitive Gram negative bacteria were recovered from 
various clinical specimens. The prevalence of AmpC β-lactamase was determined using a combination 
of disc antagonism test and cefoxitin-cloxacillin inhibition test. Disc susceptibility test was performed on 
all isolates using standard techniques. 
Results: Cefoxitin-cloxacillin inhibition test detected more AmpC β-lactamase than other tests. The 
prevalence of AmpC β-lactamase did not differ significantly between both genders and between in-
patients and out-patients (p>0.05). Isolates recovered from sputum had significantly higher prevalence 
of AmpC β-lactamase producers compared with isolates from other clinical specimens (p=0.0484). The 
prevalence of AmpC production was significantly higher among isolates of Pseudomonas aeruginosa 
than other isolates (p = 0.0085). Isolates that produced AmpC β-lactamase were more susceptible to 
the test cephalosoprins. 
Conclusion: An overall prevalence of AmpC β-lactamase (15.23 %) was observed in this study. 
Pseudomonas aeruginosa was the most prevalent producer of AmpC enzymes. Prudent use of 
antibiotics is advocated. 
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Drug and multidrug resistant bacterial pathogens 
that are causative agents of infectious disease 
constitute a serious public health concern [1]. 
The development of new antibiotics has been 
accompanied by the steady increase of 
antibiotic-resistant bacterial strains and the 
diversity of mechanisms used by bacteria to 
surpass the lethal effect of these compounds [2]. 
Many bacterial species show multi- or pan-
resistant phenotypes and most of these multidrug 
resistant (MDR) bacteria can cause life-
threatening infections, and are of major concerns 
both in the hospital and the community [3,4]. The 
prevalence of multidrug-resistant Gram-negative 
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bacteria has increased continuously over the 
past few years [5]. 
 
Beta lactam antibiotics are still the most 
predominantly prescribed antibiotics to treat 
bacterial infections, especially in Nigeria 
hospitals [6,7]. Over the last two decades many 
new β-lactams have been developed that were 
specifically designed to be resistant to hydrolytic 
actions of β-lactamases [8]. But a new type of β-
lactamase such as AmpC β-lactamase has 
emerged [8].  AmpC β-lactamases are class C or 
group I cephalosporinases that confer resistance 
to a wide variety of β-lactam antibiotics including 
penicillins, cephalosporins, oxyimino-
cephalosporins (e.g., ceftriaxone, cefotaxime, 
and ceftazidime), cephamycins (e.g., cefoxitin 
and cefotetan), and monobactams (aztreonam).  
The activity of this enzyme is not affected by the 
ESBL inhibitor clavulanic acid, sulbactam and 
tazobactam [5,9-11]. Infections caused by 
AmpC-positive bacteria are therefore of particular 
clinical and epidemiological importance and as 
they cause higher patient morbidity and mortality 
[12]. Indeed, mortality rates of 14.3 – 46 % have 
been reported [13]. AmpC β-lactamases are not 
detected in routine susceptibility test and are 
typically associated with multiple antibiotic 
resistances, leaving few therapeutic options [14-
16]. Therefore, detecting AmpC-positive bacteria 
is clinically important, not just because of their 
broader cephalosporin resistance, but also 
because carbapenem resistance can arise in 
such strains by further mutations, resulting in 
reduced porin expression as well as false 
positive extended spectrum β-lactamase 
screening test [5,17]. Against this background 
and lack of data on the prevalence of AmpC β-
lactamase in Benin City, Nigeria, this study was 
conducted to determine the prevalence of AmpC 
β-lactamase among Gram negative bacterial 
recovered from clinical specimens. The 
susceptibility profiles of AmpC-positive and 






A total of 256 consecutive non–repetitive 
bacterial isolates recovered from various clinical 
specimens from patients attending University of 
Benin Teaching Hospital, Benin City (UBTH), 
Benin City, Nigeria, were used for this study. The 
isolates included Escherichia coli, Klebsiella 
species, Citrobacter species, Proteus species, 
Providencia species, Acinetobacter species, 
Alcaligenes species and Pseudomonas 
aeruginosa. All isolates were identified using 
standard techniques [18]. 
 
Detection of AmpC β-lactamase 
 
The presence of AmpC β-lactamase was 
detected by the combination of the methods of 
Livermore and Brown [19] and Peter-Getzlaff et 
al [20]. Briefly, test organisms were emulsified in 
sterile water and the turbidity matched with 0.5 
McFarland standards. Once matched, a sterile 
cotton wool swab was dipped in the organism 
suspension and excess liquid was removed by 
turning the swab on side of the test tube. The 
entire surface of Mueller–Hinton agar plate was 
seeded by swabbing in three directions with the 
swab. A 30 µg cefoxitin disc was placed on the 
seeded plated and flanked on either side by a 30 
µg ceftazidime and a 30 µg ceftriaxone discs 
placed 15 mm from the cefoxitin disc. Another 30 
µg cefoxitin disc supplemented with 200 µg 
cloxacillin was placed in another area of the 
seeded plate. The plates were incubated at 37 
oC overnight. AmpC production is inferred if there 
was blunting or flattening of the zone of inhibition 
of either the ceftazidime or ceftriaxone or both 
[disc antagonism test (DAT), 19]. Comparing the 
zone diameters of the cefoxitin discs with and 
without cloxacillin infers AmpC β-lactamase 
production if the difference in the zone diameters 
is ≥4 mm [cefoxitin-cloxacillin inhibition test 
(CCIT), 20].  An isolate that is positive for the 
disc antagonism test or the cefoxitin-cloxacillin 
inhibition test or both was considered positive 
AmpC β-lactamase. 
 
Disc susceptibility testing 
 
Disc susceptibility tests were performed on all 
bacterial isolates using the British Society for 





The DAT method detects chromosomal-mediated 
AmpC production while the CCIT method detects 
plasmid-mediated AmpC production. Prevalence 
of AmpC was determined by adding AmpC 
producers detected by DAT alone, CCIT alone 
and where both methods detected AmpC in an 
isolate. The total number was expressed as a 
percentage of 256. The data obtained were 
analyzed with Chi square (X2) test and odds ratio 
analysis using the statistical software INSTAT® 
(Graph Pad Software Inc, La Jolla, CA, USA). 
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A total of 39 (15.23 %) out of the 256 Gram 
negative bacterial isolates were positive for 
AmpC β-lactamase. Of these isolates that were 
positive for AmpC β-lactamase, the disc 
antagonism test detected 2 (0.78 %), the 
cefoxitin-cloxacillin inhibition test detected 29 
(11.33 %) while 8 (3.13 %) were detected by 
both methods, and the difference was statistically 
(p < 0.0001) significant (Table 1). 



















DAT + CCIT 256 8(3.13) 
2: p < 0.0001 
 
The distribution of AmpC producing Gram 
negative bacterial isolates in relation to gender of 
patients and source of isolates is shown in Table 
2. The prevalence of AmpC β-lactamase did not 
differ significantly (p = 0.9099) between isolates 
recovered from males (14.53 %) and those 
recovered from females (15.83 %). The 
prevalence of AmpC production was higher 
among isolates recovered from in-patients (16.33 
%) compared with those recovered from out-
patients (11.67 %) and isolates from in-patients 
were associated with AmpC production (OR = 
1.477, 95 %CI = 0.616, 3.543), although, it was 
not statistically significant (P = 0.5006). 
 
AmpC production was highest among isolates 
recovered from sputum (50.00 %) followed by 
isolates recovered from the ear (20.00 %) and 
the distribution of AmpC production differ 
significantly (p = 0.0484) between isolates 
recovered from various clinical specimens (Table 
3). 
The prevalence of AmpC production among the 
Gram negative bacteria used in this study is 
shown in Table 4. Pseudomonas aeruginosa 
were the most prevalent producers of AmpC 
(37.14 %) followed by Providencia species. All 
strains of Acinetobacter species and Alcaligenes 
species used in this study did not produce AmpC 
β-lactamase. There was a significant difference 
in the prevalence of AmpC β-lactamase among 
the various genera of Gram negative bacteria 
used in this study (p = 0.0103). 
 
The susceptibility profiles of AmpC-producing 
and non-producing Gram negative bacteria are 
shown in Tables 5 and 6 respectively. Generally, 
the susceptibility profiles ranged from poor to 
high depending on the isolates and the 
antibacterial agent and isolates that produced 





Of the 256 Gram negative bacteria used for this 
study, DAT method detected 2(0.78 %) AmpC 
producers, CCIT method detected 29 (11.33 %) 
producers while both methods detected 8(3.13 
%) AmpC producers simultaneously. Usually, 
AmpC β-lactamase are either plasmid-or 
chromosomal-mediated [5,12]. DAT detects 
chromosomally-mediated AmpC production 
[11,19] while CCIT detects plasmid-mediated 
AmpC production [12]. This indicates that both 
chromosomal and plasmid-mediated AmpC β-
lactamase were present, though the prevalence 
of plasmid-mediated AmpC β-lactamase was 
significantly higher (p < 0.0001). This is 
worrisome as this mode of resistance can easily 
be transferred among Gram negative bacteria. It 
has been reported that such plasmids can 
harbour high number of resistant genes 
associated with carbapenem resistance, ESBL 
genes,     aminoglycoside      resistant     genes, 
 
Table 2: Distribution of AmpC producing isolates in relation to gender of patients and source of isolates 
 
Odds ratio (OR) and corresponding confidence intervals (CI) and p values were calculated based on gender 
(male versus female) or in-patients versus out-patienst data  
 
Characteristics  No. tested No. positive for 
AmpC (%) 
OR 95%CI P-value 
Gender       
      Male 117 17(14.53) 0.904 0.455,1.797 0.9099 
      Female 139 22(15.83)    
Source of isolates      
       In-patient 196 32(16.33) 1.477 0.616,3.543 0.5006 
       Out-patient 60 70(11.67)    
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Table 3: Prevalence of AmpC β-lactamase among Gram negative bacteria 
isolated from different clinical specimens 
 
Specimen  No. of isolates No. positive AmpC (%) P-value 
Ear swabs 20 4(20.00)  
Genital swabs 16 2(12.50)  
Urine 109 12(11.01) 0.0484 
sputum 8 4(50.00)  
Wound/Others 103 17(16.50)  
Total 256 39(15.23)  
Table 4: Prevalence of AmpC production among the 
Gram-negative bacteria 
 
Organism  No. 
tested 
No. positive for 
AmpC (%) 
Escherichia coli  76 8(10.53) 
Klebsiella species  91 13(14.29) 
Citrobacter species  9 2(22.22) 
Proteus species  25 2(8.00) 








p=0.010, *These values were not used in the statistical 
analysis using chi square test 
 
macrolide resistant genes, rifampin and 
sulfamethoxazole resistance genes as a source 
of multi-drug resistance [22,23]. This limits 
therapeutic options. Chromosomal-mediated 
AmpC β-lactamases are inducible and such 
isolates are resistant but produce small amounts 
AmpC β-lactamase [5,19]. However, AmpC-
inducible species segregate derepressed 
mutants which produce their AmpC enzymes 
copiously without induction, and these mutants 
are resistant to almost all penicillins and 
cephalosporins [24,25]. Therefore, detection and 
differentiation of both chromosomal- and 
plasmid-mediated AmpC β-lactamase is 
essential. 
 
The prevalence of AmpC β-lactamase in this 
study was 15.23 % (39/256). This is lower than 
the 31% and 37 % previously reported [13,26]. 
The difference could be due to geographical 
location or the manner in which the prevalence 
was determined. Black et al [13] study was 
conducted in the United States of America, 
Shivanna and Rao [26] study was conducted in 
India, while this study was conducted in Nigeria. 
In both Black et al [13] and Shivanna and Rao 
[26] study, the prevalence of AmpC β-lactamase 
were calculated from isolates resistant to 
cefoxitin while the prevalence of AmpC-positive 
in this study was calculated from the total 
isolates used. The prevalence of AmpC β-
lactamase observed in this study was higher than 
that reported in Kano (2 %) [27]. This may 
indicate that regions within the same country 
may have different prevalence rates of AmpC-
positive isolates, and this may reflect the degree 
of antibiotic abuse in the different regions of the 
country as antibiotics use is unregulated in 
Nigeria. 
 
There was no significant difference in the 
prevalence of AmpC β-lactamase between 
isolates recovered from males and females (p = 
0.9099). This agrees with the findings of Yusuf et 
al [27]. Similarly, there was no significant 
difference (p = 0.5006) in the prevalence of 
AmpC β-lactamase among isolates recovered 
from in-patients and out-patients. 
 
A similar finding was recently reported in relation 
to ESBL in our institution [28]. Prior use of broad 
spectrum antibiotics such as β-lactam antibiotics 
(cephalosporins) are risk factors for ESBL 
[29,30]. Exposure to β-lactam antibiotics can 
result in AmpC β-lactamase production [31]. In 
Nigeria, extended-spectrum cephalosporins and 
fluoroquinolones are widely used as broad 
spectrum antibiotics and remain the drugs of 
choice to treat infections caused by various 
Gram negative pathogens [32]. This together 
with the unregulated use of antibiotics in Nigeria 
may explain this finding.  
 
In this study isolates recovered from sputum had 
the highest prevalence of AmpC production. This 
is not in agreement with the findings of Yusuf et 
al [27] where isolates from urine were the 
predominant producers of AmpC β-lactamase. 
No reason could be adduced for this difference, 
albeit, the prevalence of AmpC β-lactamase 
differ significantly among Gram negative bacteria 
recovered from various clinical specimens (p = 
0.0484). 
 
The prevalence of AmpC β-lactamase differ 
significantly (p = 0.0103) among the genera of 
Gram negative bacteria with strains of 
Pseudomonas aeruginosa been the most 
prevalent producers of AmpC β-lactamases. 
AmpC β-lactamase has been reported to be 
chromosomally-mediated in Pseudomonas 
species [33]. However, strains of Pseudomonas 
aeruginosa harboured both chromosomal and  
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Table 5: Susceptibility profiles of AmpC β-lactamase producers 
 

















Escherichia coli (n = 8) 1(12.5) 2(25) 5(62.5) 0(0.0) 3(37.5) 3(37.5) 1(12.5) 4(50.0) 
Klebsiella species (n = 13) 4(30.8) 9(69.2) 9(69.2) 3(23.1) 4(30.8) 9(69.2) 3(23.1) 8(61.5) 
Citrobacter species (n = 2) 1(50.0) 1(50.0) 1(50.0) 0(0.0) 0(0.0) 1(50.0) 0(0.0) 2(100.0) 
Proteus species (n = 2) 1(50.0) 1(50.0) 1(50.0) 0(0.0) 1(50.0) 0(0.0) 0(0.0) 1(50.0) 
Providencia species (n = 1) 0(0.0) 1(100.0) 1(100.0) 0(0.0) 1(100.0) 0(0.0) 0(0.0) 1(100.0) 
Pseudomonas aeruginosa (n = 13) 3(23.11) 9(69.2) 11(84.6) 5(38.5) 2(15.4) 5(38.5) 0(0.0) 11(84.6) 
Key: CRO-Ceftriaxone, CAZ-Ceftazidime, AUG-Augmentin, GEN-Gentamicin, CPR-Ciprofloxacin, CRX-Cefuroxime, CXM-Cefixime and OFX-Ofloxacin 
 
Table 6: Susceptibility profile of non-AmpC β-lactamase producers 
 

















Escherichia coli (n = 68) 15(22.1) 29(42.7) 30(44.1) 15(22.1) 17(25) 21(30.9) 10(14.7) 27(39.7) 
Klebsiella species (n = 78) 13(16.7) 20(25.6) 28(35.9) 8(10.3) 12(15.4) 16(20.5) 8(10.3) 17(21.8) 
Citrobacter species (n = 7) 0 3(42.9) 1(14.3) 1(14.3) 3(42.9) 1(14.3) 0 2(28.6) 
Proteus species (n = 23) 4(17.4) 7(30.4) 12(52.2) 2(8.7) 3(13) 7(30.4) 3(13) 9(39) 
Providencia species (n = 3) 0 0 2(66.7) 0 0 1(33.3) 0 1(33.3) 
Acinetobacter species (n = 5) 0 3(60) 4(80) 2(40) 3(60) 1(20) 0 1(20) 
Alcaligenes species (n = 11) 0 2(18.2) 2(18.2) 2(18.2) 2(18.2) 3(27.3) 1(9.1) 6(54.5) 
Pseudomonas aeruginosa (n = 22) 1(4.6) 10(45.5) 7(31.8) 2(9.1) 1(4.6) 4(18.2) 1(4.6) 9(40.9) 
Key: CRO-Ceftriaxone, CAZ-Ceftazidime, AUG-Augmentin, GEN-Gentamicin, CPR-Ciprofloxacin, CRX-Cefuroxime, CXM-Cefixime and OFX-Ofloxacin 
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plasmid-mediated AmpC β-lactamase. Strains of 
Acinetobacter species used in the study were 
negative for AmpC β-lactamase. However, other 
authors have reported Acinetobacter species as 
producers of AmpC β-lactamase [34]. Molecular 
studies are needed to verify this as they are seen 
as the gold standard in AmpC β-lactamase 
detection [33]. The susceptibility profiles of 
AmpC β-lactamase-producing Gram negative 
bacteria reveals poor to high activity with β-
lactamase antibiotics.  
 
AmpC producers have been reported to be 
susceptible to extended-spectrum cepholospo-
rins in-vitro [35] but when these β-lactam drugs 
are used they result in treatment failure [20]. 
Therefore, these agents will not be useful in 
treating infections caused by these organisms. 
Ofloxacin was the most active agents against 
AmpC-producing Gram negative bacteria. 
Among the non-AmpC-producing Gram negative 
bacteria, the susceptibility profiles were generally 
poor, indicating higher level resistance, probably 
due to unregulated use of antibiotics and over 
the counter sales of antibiotics without 
prescription [36-38], and treatment of patients by 





An overall prevalence of AmpC β-lactamase of 
15.23 % has been observed in this study. 
Pseudomonas aeruginosa is the most prevalent 
producer of AmpC enzymes. Prudent use of 
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